 |
|
|
| |
The Effect of Renal Impairment and End Stage Renal Disease on the Single-Dose Pharmacokinetics of GS-7977
|
| |
| |
Reported by Jules Levin
EASL 2012 April 18-22 Barcelona Spain
M. Cornpropst1, J. Denning1, D. Clemons1, T. Marbury2, H. Alcorn3, W. Smith4, M. Sale5, L. Fang6, M. Berrey7, W. Symonds1
1Gilead Sciences Inc., Durham, NC, USA, 2Orlando Clinical Research Center, Orlando, FL, USA, 3DaVita Clinical Research, Minneapolis, MN, USA, 4New Orleans Center for Clinical Research at the University of Tennessee Medical Center, Knoxville, TN, USA, 5Next Level Solutions, Raleigh, NC, USA, 6Pharstat, Inc., Research Triangle Park, NC, USA, 7Pharmasset, Inc., Durham, NC, USA
Reference
1. Lawitz E et al., EASL 2011;
2. Gane E et al., AASLD 2011;
3. Lalezari J et al., EASL 2011;
4. Lawitz E et al, AASLD 2011
|
| |
|
|
|
|
|
